Stocktoria

Phathom Pharmaceuticals, Inc. PHAT

Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-10-25
Chart by TradingView
4/9
Piotroski F — financial health
-21.03
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$175.1M$55.3M$682,000$0
Gross profit$152.5M$47.3M$515,000$0
Operating income-$160.0M-$277.5M-$167.3M-$172.4M-$135.1M
Net income-$221.2M-$334.3M-$201.6M-$197.7M-$143.9M
Operating cash flow-$166.8M-$266.8M-$137.6M-$146.5M-$148.5M
Free cash flow-$167.0M-$266.9M-$139.2M-$147.6M-$148.8M
Total assets$259.1M$378.3M$413.8M$164.8M$189.4M
Total liabilities$697.3M$631.9M$486.6M$239.6M$117.3M
Shareholders' equity-$438.2M-$253.6M-$72.8M-$74.8M$72.2M
Ratios
Gross margin87.1%85.6%75.5%
Operating margin-91.4%-502.2%-24532.6%
Net margin-126.3%-605.1%-29558.9%
FCF margin-95.4%-483.1%-20412.6%
Return on assets-85.4%-88.4%-48.7%-120.0%-76.0%
Return on equity50.5%131.8%277.1%264.3%-199.4%
Debt / equity-0.48×-0.79×-1.89×-1.27×1.24×
Current ratio1.734.2010.256.129.86
Revenue growth216.9%8001.5%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC305,800$3.4M

Why these scores methodology →

Piotroski F-score: 4/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -21.03 (distress)

  • Working capital / assets 0.374
  • Retained earnings / assets -5.727
  • EBIT / assets -0.617
  • Equity / liabilities -0.628

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001783183 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.